Irbesartan in patients with atrial fibrillation. - Wikidata - awgldk - TriplyDB

Irbesartan in patients with atrial fibrillation.

Irbesartan in patients with atrial fibrillation.

http://www.wikidata.org/entity/Q44629767

about

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Atrial fibrillation in heart failure: what should we do?Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials The past, present and future of renin-angiotensin aldosterone system inhibition Novel pharmacological targets for the rhythm control management of atrial fibrillation.Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.Left Ventricular Filling Pressure as Assessed by the E/e' Ratio Is a Determinant of Atrial Fibrillation Recurrence after Cardioversion.2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: A meta-analysis and systematic review of randomized controlled trials.The role of the renin-angiotensin system blocking in the management of atrial fibrillation.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope.Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.Critical review of cancer risk associated with angiotensin receptor blocker therapy.The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation.Atrial fibrillation in heart failure.Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.A review of the epidemiological profile of patients with atrial fibrillation and heart failure.Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation.Atrial fibrillation in heart failure: drug therapies for rate and rhythm control.During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate?Novel therapeutic targets in the management of atrial fibrillation.Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials.The cost-effectiveness of irbesartan for hypertension.Blood pressure control versus atrial fibrillation management in stroke prevention.Device-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology.A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.Prerequisites for Exploring Predictors of Chronic Atrial Fibrillation Recurrence After Ablation Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.

P2860

Q26768696-2BA0D329-7C7B-4B1B-9EE1-AEF74D448E75 Q26784426-673C75DF-90C7-4826-ABB0-DF800EA2418F Q26851803-8B8671CE-12EF-49C4-AF7E-C16FF66DFD0F Q28087109-62771B5A-CBF2-4EE6-B1A4-69E93A03F5C6 Q34094354-AAE3A08B-CB34-4DDF-ACD9-69C17E31B230 Q35489060-5F80A874-7296-4D2A-B3EE-9D7CCDDD9FA3 Q36058755-F6AEDEF2-2C5A-4606-8C8A-8CFE2C6FF185 Q36418761-69A2BB68-642A-45A1-8A72-86519DCFE409 Q36572355-22AD8C41-F958-496F-BD00-DDD23BD71C7B Q36701732-A4174A7C-5A5B-48F1-BC37-E949C35BE9F7 Q36824736-9DCF24DB-951E-4CE7-BD4D-B3EBFCE09E77 Q36918956-7ABEE270-3E56-4432-8A1B-9CC809609E34 Q37066818-2B6DB26C-81F5-4858-96C1-9D1229DCD2CB Q37078083-A1178D29-9B08-4389-8508-A94F1D8A375F Q37166906-8C6DDB3C-6340-434D-A9A4-3304C93832EE Q37225236-81EA3966-E36C-4506-902B-B015A6739DE4 Q37496298-DEDA97CA-A8D9-4DDF-B36E-3F2F3E1FC1B5 Q37691484-400F3C4F-ED9E-415B-A4C4-B6DDA4BE2FB9 Q37868371-4439147D-01C0-4E97-B33C-AA400169CB0E Q37947093-AC7323F2-2E5A-4590-A6AB-7E516C66CA5C Q37963121-774A6A33-9BEC-4A72-AF60-031B7D9CC904 Q37975493-14178376-146A-4A21-81A4-EB674443D18F Q38011656-E38280B2-344E-4C0A-96C7-6BE554533085 Q38016454-A1399DDD-DFF3-42AC-A67C-D4F1DDC6AFBE Q38025390-8FC019AD-C18B-403E-A8AA-DF8887DECD0C Q38032181-A1EEDEF5-752B-44A5-9EF9-773B09887642 Q38048843-A3D1E964-2302-4584-81E4-429F1D8F9A5D Q38055506-1E00ADE0-F6ED-4A92-AFB7-2720A00B91E6 Q38056112-4323DBA7-1014-47E4-8DEC-121B75D036D8 Q38108265-5826C77C-58C7-497F-AE10-59B34D3DFACB Q38128978-BADFCD39-DE11-45EA-A10B-C0DD466FF29A Q38236746-43DD1E80-7333-4390-A1D5-29B93B9118B0 Q38267697-4FDB437A-FD11-4040-B1F7-E9D0D7E9D54E Q38363840-7AA000D2-634E-4881-AEC3-95DB22DC6723 Q38429854-3EFCA02A-89E0-439A-AA0F-E7ACD60A94FE Q38719258-56EAFB73-576C-4053-B84E-E0957CBF15D5 Q38770111-D5B7CD0B-95AF-4C72-BAEA-EF0160FF41E9 Q38790555-4A8FA6B2-DE06-48EB-811F-AF3591DAB559 Q38813385-3BCE4D36-AA4A-4348-A1BD-D014484EA9DD Q38826605-F074D5CC-8DD9-4A6D-B1C9-E98A5AF44679

P2860

Irbesartan in patients with atrial fibrillation.

http://www.wikidata.org/entity/Q44629767

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Irbesartan in patients with atrial fibrillation.

@en

Irbesartan in patients with atrial fibrillation.

@nl

type

label

Irbesartan in patients with atrial fibrillation.

@en

Irbesartan in patients with atrial fibrillation.

@nl

prefLabel

Irbesartan in patients with atrial fibrillation.

@en

Irbesartan in patients with atrial fibrillation.

@nl

P1433

Q44629767-44FBCA78-7FA3-4B2B-8BB7-6B9496B71FED

P1476

Q44629767-FBBCB89F-3F78-4367-B5AF-7BE297614AEC

P2093

Q44629767-543FD66F-8B53-4EDA-BA76-D5A48C239C42

Q44629767-5B44678A-BA18-4E3D-ABAE-0F87B40F0327

Q44629767-65A9B1B2-4BAB-433C-BD81-FE221BAAB4CF

Q44629767-7E792F86-C8BB-4756-84CC-FF6512F3F95D

Q44629767-805ED03B-42F2-4273-B074-C0ED9115FBAD

Q44629767-BE5603C2-25B9-40B1-A5B2-D7671A5505AC

Q44629767-EE050507-3AE6-402C-96D8-8473F6AF2E7A

Q44629767-FF58597E-288E-45B3-AEB9-632C8A20F4A8

P304

Q44629767-552C4194-871B-47AE-9D6B-0AA5EF061542

P31

Q44629767-7FA86269-5D25-421A-BC4C-FEABBB53B215

P356

Q44629767-8298A59B-10BF-4CA8-B942-08AB75AB06CA

P407

Q44629767-8B1FF7BA-72D0-4BE8-91AA-775817417FE3

P433

Q44629767-ABA02CDC-9388-4267-8877-9424B5E1054B

P478

Q44629767-36B5F479-BFEE-4918-8E89-7EE54C4ADDA0

P50

Q44629767-41BFFE07-143B-457D-9CA9-F5A4AE2DE621

Q44629767-6AF999A1-D7E4-404F-A5BF-930A7893AB85

Q44629767-D4A61C54-52F0-4D4F-B561-7300C40A1A0E

P577

Q44629767-59DA5235-4E32-4D6B-B771-D7C5BDE1A28F

P698

Q44629767-0B49B302-9101-4941-A897-458AF71F9700

P356

P1433

The New England Journal of Medicine

P1476

Irbesartan in patients with atrial fibrillation.

@en

P2093

ACTIVE I Investigators

http://www.w3.org/2001/XMLSchema#string

Campbell D Joyner

http://www.w3.org/2001/XMLSchema#string

Jeff S Healey

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Marcus Flather

http://www.w3.org/2001/XMLSchema#string

Robert G Hart

http://www.w3.org/2001/XMLSchema#string

Stefan H Hohnloser

http://www.w3.org/2001/XMLSchema#string

Stuart J Connolly

http://www.w3.org/2001/XMLSchema#string

P304

928-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1008816

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Susan Chrolavicius

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21388310

http://www.w3.org/2001/XMLSchema#string